Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pasala Ravichandran

Thoracic Surgery (Cardiothoracic Vascular Surgery) Portland, OR Medical Doctor

NPI 1487669990 CMS profile 113256

2222 Nw Lovejoy St, Suite 315, Portland, OR 97210

Open in the dashboard

General payments

$6,935

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pasala Ravichandran of Portland, OR is reported in the CMS Open Payments database as having received $6,935 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,232 59
2024 General $975 30
2023 General $635 21
2022 General $1,243 36
2021 General $164 6
2020 General $211 8
2019 General $474 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pasala Ravichandran
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Pasala Ravichandran were reported at $3,232. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Pasala Ravichandran Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $474 $886 $178–$3,167 $163
2020 $211 $341 $108–$1,605 $114
2021 $164 $453 $125–$1,886 $132
2022 $1,243 $695 $180–$2,566 $149
2023 $635 $745 $205–$2,662 $160
2024 $975 $799 $214–$2,967 $164
2025 $3,232 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $2,821 83 payments
  2. CryoLife, Inc. $1,455 10 payments
  3. Abiomed $1,204 34 payments
  4. Atricure, Inc. $320 6 payments
  5. Ethicon US, LLC $192 4 payments
  6. Abbott Laboratories $174 3 payments
  7. Medtronic, Inc. $107 4 payments
  8. Baxter Healthcare $94 5 payments
  9. Medtronic Vascular, Inc. $92 4 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $66 4 payments
  11. Other $411 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,857 171 payments
  2. Travel and Lodging $1,078 3 payments
Products named General payments · program years 2019–2025
  1. AMDS-Ascyrus Medical $1,409 7 payments
  2. SAPIEN 3 Ultra RESILIA $1,025 35 payments
  3. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $403 15 payments
  4. Impella $341 12 payments
  5. EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE (THV) $303 5 payments
  6. MITRIS RESILIA Mitral Valve $290 4 payments
  7. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $209 7 payments
  8. SYNERGY ABLATION SYSTEM $146 1 payment
  9. Trifecta GT Tissue Heart Valve $111 1 payment
  10. VISTASEAL $100 1 payment
  11. Other $1,746 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$110,932

Medicare's payments for the services billed

Medicare patients

146

Average age 78

Services billed

203

54 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 42%
Ischemic heart disease 40%
Heart failure 30%
Atrial fibrillation 27%
Diabetes 22%
Arthritis 22%
Chronic kidney disease 18%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CLEVIPREX
  • CHIESI USA, INC. $14
$14 — —
KENGREAL
  • CHIESI USA, INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record